Perfuse Therapeutics

Executive Summary

Perfuse Therapeutics is a private biopharmaceutical company pioneering a novel approach to treating ocular diseases by targeting retinal ischemia. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company is developing a first-in-class endothelin antagonist designed to improve blood flow to the retina, addressing the underlying ischemic pathology in conditions such as glaucoma and diabetic retinopathy. These two diseases represent leading causes of blindness globally, and current treatments primarily manage symptoms rather than the root cause of reduced perfusion. Perfuse's therapeutic strategy aims to preserve vision by restoring normal hemodynamics in the microvasculature of the eye, offering a potential disease-modifying alternative for millions of patients. As a preclinical-stage company with no disclosed clinical data, Perfuse Therapeutics is at an early but promising juncture. Its lead candidate has shown preclinical proof-of-concept in enhancing retinal blood flow, and the company is likely preparing to advance into human trials. The pressing unmet need in ocular ischemic diseases, combined with the novelty of targeting the endothelin pathway, positions Perfuse as an attractive platform for investors seeking high-risk, high-reward opportunities in ophthalmology. Upcoming milestones, including regulatory filings and initial clinical studies, will be critical to validating its technology and de-risking the investment thesis.

Upcoming Catalysts (preview)

• Q2 2026IND Filing for Lead Endothelin Antagonist80% success
• Q3 2026Phase 1 Clinical Trial Initiation70% success
• Q4 2026Early Preclinical Data Publication or Presentation90% success